Assessment of risk factors for the development of arterial hypertension and ischemic cerebrovascular events (review)
Cardiovascular diseases are a leading public health problem worldwide. Hypertension is closely associated with the development of cerebrovascular events. Stroke is characterized by high mortality and long-term disability. The effectiveness of the prevention of ischemic brain events depends on a thorough study of risk factors, comorbidities, and biomarkers in patients with hypertension. The review examines the current understanding of the risk factors for arterial hypertension and ischemic cerebrovascular events. Questions about the role of concomitant pathology and serum biomarkers of vascular damage in the development of ischemic stroke are highlighted. The work on the relationship between arterial hypertension and ischemic stroke is considered.
Golovina N.I., Matveenko M.S., Kliushnikov N.I. 2021. Assessment of risk factors for the development of arterial hypertension and ischemic cerebrovascular events (review). Challenges in Modern Medicine. 44(3): 269–277 (in Russian). DOI: 10.52575/2687-0940-2021-44-3-269-277
While nobody left any comments to this publication.
You can be first.
Bunova S.S., Zhernakova N.I., Fedorin M.M, Skirdenko Yu.P., Osipova O.A. 2020. Effektivnaya antigipertenzivnaya terapiya: fokus na upravlenie priverzhennost'yu [Effective antihypertensive therapy: focus on adherence management]. Kardiovaskulyarnaya terapiya i profilaktika. 19 (5): 259–266. doi: 10.15829/1728-8800-2020-2663.
Osipova O.A., Gosteva E.V., Chefranova Zh.Yu., Zhernakova N.I., Lykov Yu.A., Avdeeva I.V. 2020. Vliyanie farmakoterapii na dinamiku markerov obmena kollagena u bol'nyh hronicheskoj serdechnoj nedostatochnost'yu s promezhutochnoj frakciej vybrosa na fone ishemicheskoj bolezni serdca v starshih vozrastnyh gruppah [Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease]. Kardiovaskulyarnaya terapiya i profilaktika. 19 (5): 2651. doi: 10.15829/1728-8800-2020-2651.
Chazova I.E., Zhernakova Yu.V. ot imeni ekspertov. 2019. Klinicheskie rekomendacii. Diagnostika i lechenie arterial'noj gipertonii. Sistemnye gipertenzii [Clinical guidelines. Diagnosis and treatment of arterial hypertension]. 16 (1): 6–31. doi: 10.26442/2075082X.2019.1.190179.
Ali I., Abuissa M., Alawneh A., Subeh O., Abu Sneineh A., Mousa S., Deeb I., Rayyan H. 2019. The Prevalence of Dyslipidemia and Hyperglycemia among Stroke Patients: Preliminary Findings. Stroke Research and Treatment, vol. 2019, Article ID 8194960, 6 pages, https://doi.org/10.1155/2019/8194960.
Bejot Y., Bailly H., Durier J., Giroud M. 2016. Epidemiology of stroke in Europe and trends for the 21st century. Presse Med. 45:391–8. doi: 10.1016/j.lpm.2016.10.003.
Bhasin A., Srivastava M.V.P., Vivekanandhan S., Moganty R., Talwar T., Sharma S., Kuthiala N., Kumaran S., Bhatia R. 2019. Vascular Endothelial Growth Factor as Predictive Biomarker for Stroke Severity and Outcome; An Evaluation of a New Clinical Module in Acute Ischemic Stroke. Neurol India. 67 (5): 1280–1285. doi: 10.4103/0028-3886.271241.
Boehme A.K., Esenwa C., Elkind M.S. 2017. Stroke Risk Factors, Genetics, and Prevention. Circ. Res. 120 (3): 472–495. doi: 10.1161/CIRCRESAHA.116.308398.
Chelluboina B., Vemuganti R. 2019. Chronic kidney disease in the pathogenesis of acute ischemic stroke. J. Cereb. Blood. Flow. Metab. 39 (10): 1893–1905. doi: 10.1177/0271678X19866733.
Cho J.H., Choi E.K., Moon I.K., Jung J.H., Han K.D., Choi Y.J., Park J., Lee E., Lee S.R., Cha M.J., Lim W.H., Oh S. 2020. Chromosomal abnormalities and atrial fibrillation and ischemic stroke incidence: a nationwide population-based study. Sci Rep. 28; 10 (1): 15872. doi: 10.1038/s41598-020-72678-0.
Christensen H., Bushnell C. 2020. Stroke in Women. Continuum (Minneap Minn). 26 (2): 363–385. doi: 10.1212/CON.0000000000000836.
Cipolla M.J., Liebeskind D.S., Chan S.L. 2018. The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation. J. Cereb. Blood. Flow. Metab. 38 (12): 2129–2149. doi: 10.1177/0271678X18800589.
Denisuk T.A., Pokrovskii M.V., Philippova O.V., Dolzhikov A.A., Korokin, M.V., Gudyrev O., Osipova O. 2015. Endothelio- and cardioprotective effects of HMG-COA reductase inhibitors under the condition of endotoxin-induced endothelial dysfunction. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 6 (5): 1542–1547.
Feigin V.L., Norrving B., Mensah G.A. 2017. Global Burden of Stroke. Circ Res. 120 (3): 439–448. doi: 10.1161/CIRCRESAHA.116.308413.
Francula-Zaninovic S., Nola I.A. 2018. Management of Measurable Variable Cardiovascular Disease' Risk Factors. Curr. Cardiol. Rev. 14 (3): 153–163. doi: 10.2174/1573403X14666180222102312.
Georgakis M.K., Malik R., Björkbacka H., Pana T.A., Demissie S., Ayers C., Elhadad M.A., Fornage M., Beiser A.S., Benjamin E.J., Boekholdt S.M., Engström G., Herder C., Hoogeveen R.C., Koenig W., Melander O., Orho-Melander M., Schiopu A., Söderholm M., Wareham N., Ballantyne C.M., Peters A., Seshadri S., Myint P.K., Nilsson J., de Lemos J.A., Dichgans M. 2019. Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals. Circ. Res. 27; 125 (8): 773–782. doi: 10.1161/CIRCRESAHA.119.315380.
Global Burden of Diseases GBD 2015. 2017. Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study. Lancet Neurol. 16 (11): 877–897. doi: 10.1016/S1474-4422(17)30299-5.
Harpaz D., Seet R.C.S., Marks R.S., Tok A.I.Y. 2020. B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor. Biosensors (Basel). 10 (9): 107. doi: 10.3390/bios10090107.
Heiss W.D. 2016. Malignant MCA Infarction: Pathophysiology and Imaging for Early Diagnosis and Management Decisions. Cerebrovascular Diseases. 41: 1–7. doi: 10.1159/000441627.
Howard V.J., Madsen T.E., Kleindorfer D.O., Judd S.E., Rhodes J.D., Soliman E.Z., Kissela B.M., Safford M.M., Moy C.S., McClure L.A., Howard G., Cushman M. 2019. Sex and Race Differences in the Association of Incident Ischemic Stroke With Risk Factors. JAMA Neurol. 76 (2): 179–186. doi: 10.1001/jamaneurol.2018.3862.
Katan M., Luft A. 2018. Global Burden of Stroke. Semin Neurol. 38 (2): 208–211. doi: 10.1055/s-0038-1649503.
Kim Y.S., Kim B.J., Noh K.C., Lee K.M., Heo S.H., Choi H.Y., Kim H.Y., Koh S.H., Chang D.I. 2019. Distal versus Proximal Middle Cerebral Artery Occlusion: Different Mechanisms. Cerebrovasc Dis. 47 (5–6): 238-244. doi: 10.1159/000500947.
Koliaki C., Liatis S., Kokkinos A. 2019. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 92: 98–107. doi: 10.1016/j.metabol.2018.10.011.
Lasek-Bal A., Jedrzejowska-Szypulka H., Student S., Wianecka A., Zarębar K., Puz P., Iesław Bal W., Pawletko K., Lewin-Kowalik J. 2019. The importance of selected markers of inflammation and blood-brain barrier damage fo short-term ischemic stroke prognosis. J. Physiol. Pharmacol. 70 (2): 209–217. doi: 10.26402/jpp.2019.2.04.
Lau L.H., Lew J., Borschmann K., Thijs V., Ekinci E.I. Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review. J. Diabetes. Investig. 2019; 10(3): 780–792. doi: 10.1111/jdi.12932.
Lei C., Wu B., Liu M., Chen Y. 2015. Association between hemoglobin A₁C levels and clinical outcome in ischemic stroke patients with or without diabetes. J. Clin. Neurosci. 22 (3): 498–503. doi: 10.1016/j.jocn.2014.08.030.
Meller A., Golab-Janowska M., Paczkowska E., Machalinski B., Pawlukowska W., Nowacki P. Reduced Hemoglobin Levels Combined with an Increased Plasma Concentration of Vasoconstrictive endothelin-1 are Strongly Associated with Poor Outcome During Acute Ischemic Stroke. Curr. Neurovasc. Res. 2018; 15 (3): 193–203. doi: 10.2174/1567202615666180726101531.
Osipova O.A., Golivets T.P., Belousova O.N., Gosteva E.V., Shepel R.N., Merezhko A.A., Fedorets V.N. 2020. Matrix metalloproteinases as collagen markers exchange with congestive cardiac insufficiency with an intermediate ejection fraction with patients with coronary heart disease and metabolic syndrome. Journal of critical reviews (JCR). 7 (10): 567–570. doi: 10.31838/jcr.07.10.112.
Pan B., Jin X., Jun L., Qiu S., Zheng Q., Pan M. 2019.The relationship between smoking and stroke: A meta-analysis. Medicine (Baltimore). 98 (12): e14872. doi: 10.1097/MD.0000000000014872.
Putaala J. 2020. Ischemic Stroke in Young Adults. Continuum (Minneap Minn). 26 (2): 386–414. doi: 10.1212/CON.0000000000000833.
Sharrief A., Grotta J.C. Stroke in the elderly. 2019. Handb Clin Neurol. 167: 393–418. doi: 10.1016/B978-0-12-804766-8.00021-2.
Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A., de Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S.E., Kreutz R., Laurent S., Lip G.Y.H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R.E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J. Hypertens. 36 (10): 1953–2041. doi: 10.1093/eurheartj/ehy339.
Wright J.T. Jr., Williamson J.D., Whelton P.K., Snyder J.K., Sink K.M., Rocco M.V., Reboussin D.M., Rahman M., Oparil S., Lewis C.E., Kimmel P.L., Johnson K.C., Goff D.C. Jr., Fine L.J., Cutler J.A., Cushman W.C., Cheung A.K., Ambrosius WT. 2015. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N. Engl. J. Med. 26; 373 (22): 2103–2116. doi: 10.1056/NEJMoa1511939.